循环肿瘤DNA基因组改变的变异等位基因分数(%ctDNA)与PET扫描中的SUVmax相关。

IF 2 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
American journal of nuclear medicine and molecular imaging Pub Date : 2021-08-15 eCollection Date: 2021-01-01
Amin Haghighat Jahromi, Matthew Zabel, Ryosuke Okamura, Carl K Hoh, Razelle Kurzrock
{"title":"循环肿瘤DNA基因组改变的变异等位基因分数(%ctDNA)与PET扫描中的SUVmax相关。","authors":"Amin Haghighat Jahromi,&nbsp;Matthew Zabel,&nbsp;Ryosuke Okamura,&nbsp;Carl K Hoh,&nbsp;Razelle Kurzrock","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The relationship between higher variant allele fraction (VAF) of genomic alterations in circulating tumor DNA (%ctDNA), an indicator of poor outcome, and maximum standardized uptake value (SUV<sub>max</sub>), the most commonly used semi-quantitative parameter in <sup>18</sup>F-FDG PET/CT, has not been studied. Overall, 433 cancer patients had blood-based next generation sequencing. Maximum and sum of %ctDNA alterations (%ctDNA<sub>max</sub> and %ctDNA<sub>sum</sub>, respectively) represent the maximum and sum of VAF, reported as a percentage. The subset of 46 eligible patients had treatment-naïve metastatic disease and PET/CT imaging, with median 13 days prior to ctDNA testing. We found a linear correlation between the maximum VAF (%ctDNA<sub>max</sub>) (as well as the sum of the VAFs (%ctDNA<sub>sum</sub>)) and SUV<sub>max</sub> of the most <sup>18</sup>F-FDG-avid lesion (r=0.43, P=0.003; r=0.43, P=0.002; respectively). Our data suggest that SUV<sub>max</sub> may be a non-invasive and readily available surrogate indicator for %ctDNA, a prognostic factor for patient survival. Since higher %ctDNA has been previously correlated with worse outcome, the relationship between SUV<sub>max</sub>, %ctDNA and survival warrants further study.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2021-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414395/pdf/ajnmmi0011-0307.pdf","citationCount":"0","resultStr":"{\"title\":\"Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUV<sub>max</sub> in PET scan.\",\"authors\":\"Amin Haghighat Jahromi,&nbsp;Matthew Zabel,&nbsp;Ryosuke Okamura,&nbsp;Carl K Hoh,&nbsp;Razelle Kurzrock\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The relationship between higher variant allele fraction (VAF) of genomic alterations in circulating tumor DNA (%ctDNA), an indicator of poor outcome, and maximum standardized uptake value (SUV<sub>max</sub>), the most commonly used semi-quantitative parameter in <sup>18</sup>F-FDG PET/CT, has not been studied. Overall, 433 cancer patients had blood-based next generation sequencing. Maximum and sum of %ctDNA alterations (%ctDNA<sub>max</sub> and %ctDNA<sub>sum</sub>, respectively) represent the maximum and sum of VAF, reported as a percentage. The subset of 46 eligible patients had treatment-naïve metastatic disease and PET/CT imaging, with median 13 days prior to ctDNA testing. We found a linear correlation between the maximum VAF (%ctDNA<sub>max</sub>) (as well as the sum of the VAFs (%ctDNA<sub>sum</sub>)) and SUV<sub>max</sub> of the most <sup>18</sup>F-FDG-avid lesion (r=0.43, P=0.003; r=0.43, P=0.002; respectively). Our data suggest that SUV<sub>max</sub> may be a non-invasive and readily available surrogate indicator for %ctDNA, a prognostic factor for patient survival. Since higher %ctDNA has been previously correlated with worse outcome, the relationship between SUV<sub>max</sub>, %ctDNA and survival warrants further study.</p>\",\"PeriodicalId\":7572,\"journal\":{\"name\":\"American journal of nuclear medicine and molecular imaging\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2021-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414395/pdf/ajnmmi0011-0307.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of nuclear medicine and molecular imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of nuclear medicine and molecular imaging","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

循环肿瘤DNA (%ctDNA)基因组改变的较高变异等位基因分数(VAF)(预后不良指标)与18F-FDG PET/CT中最常用的半定量参数最大标准化摄取值(SUVmax)之间的关系尚未研究。总共有433名癌症患者进行了基于血液的下一代测序。%ctDNA改变的最大值和总和(分别为%ctDNAmax和%ctDNAsum)代表VAF的最大值和总和,以百分比报告。46例符合条件的患者子集患有treatment-naïve转移性疾病和PET/CT成像,中位时间为ctDNA检测前13天。我们发现最大VAF (%ctDNAmax)(以及VAF (%ctDNAsum)的总和)与最18F-FDG-avid病变的SUVmax呈线性相关(r=0.43, P=0.003;r = 0.43, P = 0.002;分别)。我们的数据表明,SUVmax可能是一种无创且易于获得的替代指标,用于检测%ctDNA,这是患者生存的预后因素。由于较高的ctDNA百分比先前与较差的结果相关,SUVmax, %ctDNA和生存之间的关系值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUV<sub>max</sub> in PET scan.

Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUVmax in PET scan.

The relationship between higher variant allele fraction (VAF) of genomic alterations in circulating tumor DNA (%ctDNA), an indicator of poor outcome, and maximum standardized uptake value (SUVmax), the most commonly used semi-quantitative parameter in 18F-FDG PET/CT, has not been studied. Overall, 433 cancer patients had blood-based next generation sequencing. Maximum and sum of %ctDNA alterations (%ctDNAmax and %ctDNAsum, respectively) represent the maximum and sum of VAF, reported as a percentage. The subset of 46 eligible patients had treatment-naïve metastatic disease and PET/CT imaging, with median 13 days prior to ctDNA testing. We found a linear correlation between the maximum VAF (%ctDNAmax) (as well as the sum of the VAFs (%ctDNAsum)) and SUVmax of the most 18F-FDG-avid lesion (r=0.43, P=0.003; r=0.43, P=0.002; respectively). Our data suggest that SUVmax may be a non-invasive and readily available surrogate indicator for %ctDNA, a prognostic factor for patient survival. Since higher %ctDNA has been previously correlated with worse outcome, the relationship between SUVmax, %ctDNA and survival warrants further study.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American journal of nuclear medicine and molecular imaging
American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
自引率
4.00%
发文量
4
期刊介绍: The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信